2. Department of Surgery, Faculty of Medicine Tripoli - Libya.
3. Department of Pharmacology, Faculty of Medical Technology, Alga-bal Algarbi University, Libya.
Background: Hepatitis C virus (HCV) therapy has been evolved over years and many parameters were used to evaluate such therapy particularly genotyping. In North Africa and Eastern Mediterranean the genotypes vary from most of world and rarely studies were conducted to assess the influence of such genotypes on the HCV therapy.
Aims: This study was designed to determine; the role of HCV genotyping in assessing the efficacy of interferon therapy and to analyze the rates of sustained virological response (SVR) in INF and PegIFN-based regimens according on HCV genotype infecting Libyan patients with chronic hepatitis C infection.
Methods: A total of 479 patients with chronic HCV registered at Tripoli Medical Centre were treated with 'INF alfa or PEG-INF- Pegylated INF alfa 2a in combination with ribavirin' for a five year period. These patients were registered and followed up from January 2007 to October 2012. The information were reviewed and data were collected from each patient regarding age, gender, ALT level, and viral load, viral genotype using qualitative PCR. The statistical analysis were carried using SPSS version 11.5.
Results: Of the patients studied 86 patients were treated with INF based regimen, only 54% of them had end treatment response (ETR) and 28% had SVR. Off 143 patients treated with peg-INF alfa 2a based therapy; 69% had ETR and 36% had SVR. The SVR of Peg-INF based regimen was higher than INF based regimen in all genotypes except for genotype 4. The relationship between SVR and gender was significant in patients who were given INF based therapy comparable to PEG INF based regimen, though the relationship between SVR and age, basal viral load and basal ALT were also reported in both regimens.
Conclusions: HCV genotyping has been found to play an important valuable role in determining the efficacy of Hepatitis C therapy. SVR vary according to the HCV genotype involved. HCV genotype 1 and 4 were found to be the prevalent resistant genotypes infecting Libyan patients. Such findings are particularly important in guiding the clinical therapy of patients infected with hepatitis C virus.
Keywords: Hepatitis C virus, interferon, Libyan patients, HCV genotypes